Published in Cancer Weekly, January 31st, 2006
"Gefitinib is effective in the treatment of advanced NSCLC. However, most studies have only investigated patients who have good performance status or are evaluable," scientists in Taiwan reported.
"This study evaluated the efficacy of gefitinib in a consecutive series of patients with NSCLC. The treatment response of all gefitinib-treated NSCLC patients from November 2001 to September 2003 at a single medical institute was retrospectively evaluated. All patients receiving at least 1 dose of gefitinib...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.